Duodenal Gist
Duodenal Gist - Related Videos
06:43
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
0 Views •
2026
This video case report demonstrates the unique management of a duodenal gastrointestinal stromal tumor with a rare, understudied, exon 8 KIT mutation. Neoadjuvant therapy resulted in a 30% reduction in tumor size, making the patient a candidate for a robotic-assisted duodenal sleeve resection instead of the more morbid pancreaticoduodenectomy.
10:41
Robotic D3 Partial Duodenal Resection with Primary Side-to-Side Anastomosis
0 Views •
2023
This protocol presents a case of a robotic partial duodenal resection with primary side-to-side duodeno-jejunal reconstruction in a patient with a 5 cm duodenal stenosis. This is done at the third duodenal segment (D3) after an endoscopic mucosal resection (EMR) for a duodenal polyp.
03:37
Application of Robot-assisted Pancreaticobiliary Junction Resection in Benign Duodenal Tumors
0 Views •
2024
The current protocol delineates the use of robot-assisted pancreaticobiliary junction resection for the surgical management of benign duodenal tumors. This approach provides an effective solution for treating these tumors while minimizing duodenal loss and reducing associated complications.
08:50
Duodenal-Jejunal Bypass Surgery in Diet-Induced Obese Diabetic Mice
0 Views •
2024
Duodenal-jejunal bypass (DJB) surgery can improve glucose metabolism and reduce insulin resistance. Here, we present a protocol to establish a stable and reliable mouse model of DJB.
06:19
Visual Evoked Potential Recordings in Mice Using a Dry Non-invasive Multi-channel Scalp EEG Sensor
0 Views •
Cited by 2 •
2018
We designed a dry-type 16 channel EEG sensor which is non-invasive, deformable, and re-usable. This paper describes the whole process from manufacturing the proposed EEG electrode to signal processing of visual evoked potential (VEP) signals measured on a mouse scalp using a dry non-invasive multi-channel EEG sensor.
FAQs
Activating alterations in KIT or PDGFRA can keep receptor signaling active, rather than allowing growth signals to remain appropriately regulated. This persistent signaling promotes uncontrolled cell growth and provides a mechanistic explanation for tumor development. Identifying the relevant alteration is also important because it may indicate whether targeted treatment such as imatinib is likely to be useful.
A key biological clue is the tumor’s connection with interstitial cells of Cajal: most GISTs either develop from these cells or resemble them. Alongside the mesenchymal classification, this relationship helps frame duodenal GIST as a connective-tissue-type tumor rather than an epithelial lesion. That distinction supports tissue analysis and immunohistochemistry during evaluation.
The anatomic location matters because it can complicate both diagnosis and treatment. Consequently, clinicians do not rely on a single piece of information: endoscopy, cross-sectional imaging, and tissue analysis are combined to characterize the lesion, while treatment planning must account for the challenges created by its duodenal site.
A diagnostic workup typically brings together endoscopy, cross-sectional imaging, and tissue analysis with immunohistochemistry. These approaches provide complementary information about the suspected lesion and its cellular features. Using them together is important because the duodenal location can make diagnosis more challenging, requiring coordinated structural and tissue-based assessment rather than reliance on one test.
Immunohistochemistry forms part of the tissue-based assessment used to evaluate duodenal GIST. When combined with broader tissue analysis, it contributes to characterizing the tumor in the context of its mesenchymal biology and relationship to interstitial cells of Cajal. Molecular assessment adds another layer by identifying alterations relevant to targeted treatment decisions.
Management may include surgical resection and targeted therapy with imatinib, but their relevance depends on the tumor’s clinical and molecular context. Imatinib is particularly pertinent when the tumor carries susceptible molecular alterations. Combining treatment planning with risk assessment supports more individualized care, which is especially important when the duodenal location complicates management.